Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.

Although the p-value of 0.206 did not reach statistical significance, potentially due to the limited sample size and insufficient statistical power, this consistent trend strongly suggests that standard chemotherapy combined with anti-angiogenic agents may provide more robust and reliable disease control in overcoming C797S-mediated resistance.

also in 111,027 other papers